Researchers have found that PP2A inactivation promotes the development of multiple cancer types including breast [29], colorectal [19], and oral cancer [30] resulting in studies to determine whether PP2A activation may serve as a potential therapeutic in breast [29], oral [30], and prostate cancers [31]. This evidence concerns the gene PTPA and Familial prostate cancer.